Company · CIK 0001806952 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Lyell Immunopharma, Inc. · LYEL
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 SForm 4 → | Sep 10, 7:37 pm EDT | David ShookChief Medical Officer | 500 | $12.70 | $6,350 | 20,423 | −2.39% | |
| Aug 21, 2026 SForm 4 → | Aug 25, 4:06 pm EDT | Lynn SeelyPresident and CEO, Director | 9,589 | $15.54 | $149,013 | 63,899 | −13.0% | |
| Aug 21, 2026 SForm 4 → | Aug 25, 4:05 pm EDT | Stephen J. HillChief Operating Officer | 989 | $15.54 | $15,369 | 16,816 | −5.55% | |
| Aug 21, 2026 SForm 4 → | Aug 25, 4:03 pm EDT | Gary K. LeeChief Scientific Officer | 1,457 | $15.54 | $22,642 | 16,220 | −8.24% | |
| Aug 10, 2026 SForm 4 → | Aug 11, 4:21 pm EDT | Veronica Sanchez BulisVP, Corporate Controller | 621 | $14.34 | $8,905 | 14,799 | −4.03% | |
| Aug 10, 2026 SForm 4 → | Aug 11, 4:20 pm EDT | Gary K. LeeChief Scientific Officer | 131 | $14.34 | $1,879 | 17,677 | −0.74% | |
| Aug 10, 2026 SForm 4 → | Aug 11, 4:18 pm EDT | Stephen J. HillChief Operating Officer | 89 | $14.34 | $1,276 | 17,805 | −0.50% | |
| Aug 10, 2026 SForm 4 → | Aug 11, 4:07 pm EDT | Lynn SeelyPresident and CEO, Director | 390 | $14.34 | $5,593 | 73,488 | −0.53% | |
| Jul 27, 2026 JForm 4 → | Jul 27, 9:14 pm EDT | Innovative Cellular Therapeutics Holdings Ltd10% Owner | 44,000 | — | — | 2,774,980 | — | |
| Jul 27, 2026 JForm 4 → | Jul 27, 7:59 pm EDT | Innovative Cellular Therapeutics Holdings Ltd10% Owner | 38,500 | — | — | 2,818,980 | — | |
| Jul 17, 2026 SForm 4 → | Jul 20, 2:55 pm EDT | Innovative Cellular Therapeutics Holdings Ltd10% Owner | 10 | $13.70 | $137 | 2,857,480 | −0.00% | 10b5-1 |
| Jul 16, 2026 SForm 4 → | Jul 17, 9:45 pm EDT | Innovative Cellular Therapeutics Holdings Ltd10% Owner | 10 | $13.73 | $137 | 2,857,490 | −0.00% | 10b5-1 |
| Jun 29, 2026 JForm 4 → | Jul 1, 12:37 pm EDT | Innovative Cellular Therapeutics Holdings Ltd10% Owner | 76,000 | — | — | 2,857,500 | — | |
| Jun 15, 2026 JForm 4 → | Jun 18, 9:59 pm EDT | Innovative Cellular Therapeutics Holdings Ltd10% Owner | 66,500 | — | — | 2,933,500 | — | late |
| Jun 10, 2026 SForm 4 → | Jun 11, 4:07 pm EDT | David ShookChief Medical Officer | 1,977 | $12.64 | $24,989 | 20,923 | −8.63% | |
| May 11, 2026 SForm 4 → | Jun 15, 6:37 pm EDT | Lynn SeelyPresident and CEO, Director | 388 | $18.91 | $7,337 | 73,878 | −0.52% | late |
| May 11, 2026 SForm 4 → | Jun 15, 6:35 pm EDT | Gary K. LeeChief Scientific Officer | 130 | $18.92 | $2,460 | 17,808 | −0.72% | late |
| May 11, 2026 SForm 4 → | Jun 15, 6:34 pm EDT | Stephen J. HillChief Operating Officer | 89 | $18.92 | $1,684 | 17,894 | −0.49% | late |
| May 11, 2026 SForm 4 → | Jun 15, 6:32 pm EDT | Veronica Sanchez BulisVP, Corporate Controller | 217 | $18.91 | $4,103 | 15,420 | −1.39% | late |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 AForm 4 → | Sep 10, 7:31 pm EDT | Jarrad Mattieu AguirreChief Medical Officer | 47,500 | — | — | 47,500 | — | |
| Jun 10, 2026 AForm 4 → | Jun 12, 4:25 pm EDT | William Jl RieflinDirector | 9,250 | — | — | 9,250 | — | |
| Jun 10, 2026 AForm 4 → | Jun 12, 4:23 pm EDT | Sumant RamachandraDirector | 9,250 | — | — | 9,250 | — | |
| Jun 10, 2026 AForm 4 → | Jun 12, 4:22 pm EDT | Elizabeth G NabelDirector | 9,250 | — | — | 9,250 | — | |
| Jun 10, 2026 AForm 4 → | Jun 12, 4:21 pm EDT | Richard KlausnerDirector | 9,250 | — | — | 9,250 | — | |
| Jun 10, 2026 AForm 4 → | Jun 12, 4:19 pm EDT | Cathy FriedmanDirector | 9,250 | — | — | 9,250 | — | |
| Jun 10, 2026 AForm 4 → | Jun 12, 4:17 pm EDT | Otis W BrawleyDirector | 9,250 | — | — | 9,250 | — | |
| Jun 10, 2026 AForm 4 → | Jun 12, 4:16 pm EDT | Mark BachledaDirector | 9,250 | — | — | 9,250 | — |